Navigation Links
Andain Inc. Announces Successful 510K Tests of its Breakthrough Miniature Disposable Insulin Pump
Date:4/10/2013

BEVERLY HILLS, California, April 10, 2013 /PRNewswire/ --

Andain Inc. (OTCQB: ANDN) ("Andain"), a company engaged in commercializing novel technologies in biotech, medical and life sciences fields through its accelerating incubator program, announces today of the successful 510K tests of its miniature disposable insulin pump.

Andain Inc. has successfully completed all of the required tests for the 510K regulation of its innovative miniature disposable insulin pump.

Andain's miniature disposable insulin pump is an ultra slim, small 'Band-Aid' patch size, fully disposable, water proof, fully programmable insulin pump designed to treat Type I and Type II diabetes for a one week period. The pump's dimensions are 49mm diameter by 7 mm thick 25 with 6CC insulin, making it very comfortable and almost unnoticeable to wear. Its ultra-low cost makes it an affordable yet clinically superior replacement for pen injector products. Smart on-line monitoring provides a real-time alert for occlusions and leakages.

The pump plug-in universal remote-control (PUR) unit provides the user, clinic, and doctor a dynamic control and on-going monitoring of the insulin treatment program.

 "Our expert team meticulously monitored all tests process and results for the 510K regulation process, and providing full safety for our diabetics type II planed clinical trials."  said Andain President and CEO Sam Elimelech .

Established in 2004 as a Nevada corporation with locations in Israel and the US, Andain Inc. (OTCBB: ANDN) commercializes novel technologies in the biotech & medical fields, specializing in identifying technical innovations and providing a unique incubator/accelerator development and industrial platform. The company also offers technical know-how and business strategy expertise to commercialize new technologies and deliver shareholder value

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Form 10-K filing and other filings with the U S. Securities and Exchange Commission (available at http://www.sec.gov/). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Contact:

Sam Elimelech
CEO
sam@andaininc.com
+972-52-67-22212


'/>"/>
SOURCE Andain Inc
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Andain Inc. the Innovative Technology Incubator, Receives DTC Eligibility
2. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
3. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
4. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
5. Misonix Announces New Distribution Agreement For Panama
6. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
9. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
10. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
11. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017 AMRI , a ... been working with the life sciences industry to improve ... 25 years, has been recognized for its excellence as ... as part of the Life Science Leader,s 2017 ... expertise, quality and reliability. "Competing with ...
(Date:3/22/2017)... STOCKHOLM , March 22, 2017 ... biopharmaceutical company developing novel anticancer therapies targeting the ... with Memorial Sloan Kettering Cancer Center to study ... p53 by APR-246. The goal of ... efficacy of APR-246 in combination with multiple other ...
(Date:3/22/2017)... Research and Markets has announced the addition of the "Global ... ... market to grow at a CAGR of 14.58% during the period ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... ... leading digital and print media enterprise focused on cancer patients, cancer centers and ... released a special 12-part educational video series, “No Ifs, Ands, or Butts,” that ...
(Date:3/22/2017)... ... 22, 2017 , ... The Rett Syndrome Research Trust (RSRT) ... that afflicts 350,000 individuals worldwide. Rett Syndrome is caused by alterations in ... females. Following a normal infancy, Rett Syndrome takes effect in toddlerhood depriving ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... to its Department of Orthopedic Surgery, Division of Hand, Upper Extremity and Microvascular ... surgery. She is board-certified in both Orthopedics and Hand Surgery. , ...
(Date:3/22/2017)... ... March 22, 2017 , ... Intrinsic Imaging, ... therapeutic experience and operational excellence in oncology clinical trials, proudly announces today that ... treatment of non-small cell lung cancer and small cell lung cancer. , Throughout ...
(Date:3/22/2017)... Norwich, NY (PRWEB) , ... March 22, 2017 , ... ... to communities in the greater Nassau County region, is embarking on a combined charity ... breast cancer. , For the last 25 years, the Great Neck Breast Cancer ...
Breaking Medicine News(10 mins):